QUOTE AND NEWS
newratings.com  Jun 13  Comment 
WASHINGTON (dpa-AFX) - EntreMed, Inc. (ENMD), a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, said that at its annual meeting of stockholders held on June 12, stockholders voted in...
StreetInsider.com  Mar 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/EntreMed%2C+Inc.+New+%28ENMD%29+Reports+Q4+Loss+of+%240.05Share/9304550.html for the full story.
Benzinga  Jan 13  Comment 
EntreMed (Nasdaq: ENMD) announced today that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application...
StreetInsider.com  Nov 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/EntreMed%2C+Inc.+New+%28ENMD%29+Reports+In-Line+Q3+EPS/8885755.html for the full story.
Benzinga  Oct 31  Comment 
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the commencement of a multi-center Phase 2 study entitled "Phase II Study of Oral...
Benzinga  Oct 21  Comment 
EntreMed (NASDAQ: ENMD) announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).  The study was led by Dr....
StreetInsider.com  Aug 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/EntreMed%2C+Inc.+New+%28ENMD%29+Narrows+Q2+Loss/8599804.html for the full story.
StreetInsider.com  May 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/EntreMed%2C+Inc.+New+%28ENMD%29+Narrows+Q1+Loss/8339331.html for the full story.
Benzinga  May 6  Comment 
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL...
Benzinga  Apr 5  Comment 
EntreMed, Inc. (NASDAQ: ENMD) announced today that its Board of Directors has appointed two new individuals as directors.  Joining the Board are James Huang and Y. Alexander Wu, Ph.D. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO...




 





References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki